Arbutus Biopharma
ABUS
ABUS
122 hedge funds and large institutions have $189M invested in Arbutus Biopharma in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 37 increasing their positions, 32 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
7% more funds holding
Funds holding: 114 → 122 (+8)
3.79% more ownership
Funds ownership: 34.65% → 38.44% (+3.8%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Holders
122
Holding in Top 10
3
Calls
$5.24M
Puts
$1.23M
Top Buyers
| 1 | +$14.1M | |
| 2 | +$11.1M | |
| 3 | +$8.05M | |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.21M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.19M |
Top Sellers
| 1 | -$6.41M | |
| 2 | -$2.54M | |
| 3 | -$1.78M | |
| 4 |
BlackRock
New York
|
-$716K |
| 5 |
Millennium Management
New York
|
-$582K |